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Abstract
Background: Proteolytic processing of mutant huntingtin (mHtt), the protein that causes Huntington’s disease (HD), is
critical for mHtt toxicity and disease progression. mHtt contains several caspase and calpain cleavage sites that generate N-
terminal fragments that are more toxic than full-length mHtt. Further processing is then required for the degradation of
these fragments, which in turn, reduces toxicity. This unknown, secondary degradative process represents a promising
therapeutic target for HD.
Methodology/Principal Findings: We have used intrabodies, intracellularly expressed antibody fragments, to gain insight
into the mechanism of mutant huntingtin exon 1 (mHDx-1) clearance. Happ1, an intrabody recognizing the proline-rich
region of mHDx-1, reduces the level of soluble mHDx-1 by increasing clearance. While proteasome and macroautophagy
inhibitors reduce turnover of mHDx-1, Happ1 is still able to reduce mHDx-1 under these conditions, indicating Happ1-
accelerated mHDx-1 clearance does not rely on these processes. In contrast, a calpain inhibitor or an inhibitor of lysosomal
pH block Happ1-mediated acceleration of mHDx-1 clearance. These results suggest that mHDx-1 is cleaved by calpain, likely
followed by lysosomal degradation and this process regulates the turnover rate of mHDx-1. Sequence analysis identifies
amino acid (AA) 15 as a potential calpain cleavage site. Calpain cleavage of recombinant mHDx-1 in vitro yields fragments of
sizes corresponding to this prediction. Moreover, when the site is blocked by binding of another intrabody, VL12.3, turnover
of soluble mHDx-1 in living cells is blocked.
Conclusions/Significance: These results indicate that calpain-mediated removal of the 15 N-terminal AAs is required for the
degradation of mHDx-1, a finding that may have therapeutic implications.
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Introduction
Huntington’s disease (HD) is caused by the expansion of a
polyglutamine (polyQ) tract in the first exon (HDx-1) of the large
protein, huntingtin (Htt) [1]. Mutant Htt protein (mHtt) perturbs
many cellular processes by both gain of toxic function and loss of
normal function. These include axonal transport, mitochondrial
metabolism, transcriptional regulation and the ubiquitin protea-
some system (UPS) [2]. There is an age-dependent accumulation
of mHtt protein in HD [3], which may be partially responsible for
the adult onset of symptoms despite the lifelong expression of
mHtt. Increasing the clearance of mHtt could prevent this
accumulation and thereby delay or prevent the onset of symptoms.
Degradation of mHtt occurs through several mechanisms,
suggesting a number of potential therapeutic opportunities for
enhancing removal. Proteases cleave Htt, generating N-terminal
fragments, some of which are more toxic than the full-length
protein [4,5,6]. Increasing polyQ tract length leads to increased
caspase and calpain activation and enhanced production of toxic
N-terminal fragments in the HD brain [7]. These fragments are
degraded by additional protease cleavage, the UPS and autoph-
agy, which can involve isolation in an autophagosome and
introduction to the lysosome by fusion, macroautophagy, or
delivery to the lysosome by chaperone proteins (chaperone-
mediated autophagy, CMA) [8]. Certain cleavage events generate
toxic fragments, and selective prevention of these events
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other, less toxic N-terminal cleavage products [9,10]. Post-
translational modifications such as phosphorylation also play a
role in regulating Htt proteolysis [11,12], and phosphorylated
mHtt can be more toxic than unphosphorylated mHtt [12]. Thus,
the dichotomy of mHtt processing: while some modifications
increase the toxicity of the protein, these more toxic forms are
intermediates in the process leading to total degradation. Since
enhancing total degradation represents a powerful therapeutic
strategy, a better understanding of this process is warranted. As the
site of the disease-causing mutation, insight into the clearance of
HDx-1 is particularly salient.
We have used intrabodies (iAbs), intracellularly-expressed
antibody fragments directed against various sites in HDx-1 to
gain such insight. Intrabodies retain the high target specificity of
antibodies but lack the immunogenic constant domains. These
reagents have shown significant promise as therapeutics for
proteinopathies including HD [13]. Moreover, iAbs are also
powerful molecular tools for probing the functions and interactions
of their targets when expressed in living cells.
We have previously shown that binding of the iAb Happ1,
which recognizes the proline rich region of HDx-1, results in a
selective increase in the turnover of the mutant form (mHDx-1)
[14,15]. Here we report on the mechanism of Happ1-induced
turnover of mHDx-1, the study of which has revealed a new
insight into mHtt cleavage.
Materials and Methods
Cell culture
HEK 293 cells (ATCC) and ST14A cells (Elena Cattaneo,
Milano, Italy) were grown in DMEM (Invitrogen) supplemented
with 10% heat inactivated fetal bovine serum, 2 mM glutamine,
1 mM streptomycin and 100 international units of penicillin
(Invitrogen). Cells were maintained in 37uC (293) or 33uC
(ST14A) incubators with 5% CO2. Transfections utilized calcium
phosphate.
Ubiquitination of Htt
HEK 293 cells were transfected with mHDx-1-GFP plus iAb
(HDx-1:iAb = VL12.3, 1:1; Happ1, 1:2). Thirty-six hours post-
transfection, cells were collected for Western blotting and
immunoprecipitation (IP) as previously described [14]. Briefly,
cells were dislodged by pipetting, pelleted by centrifugation, rinsed
with PBS, and lysed by sonication in lysis buffer. Insoluble material
was removed by additional centrifugation, and the protein
concentration was determined by BCA assay (Pierce). Htt protein
was immunoprecipitated from the lysate by combining 400 mg
lysate protein with 50 mg anti-GFP antibody (Invitrogen) conju-
gated to protein G sepharose beads (Sigma) and rocking for 4 hrs
at RT. Beads were washed 4 times in PBS containing 0.1% Triton
X100 to remove unbound protein. Seventy-five mg total lysate
protein samples and bound IP samples were boiled in 6X protein
loading buffer containing 20% b-mercaptoethanol (BME), sepa-
rated by polyacrylamide gel electrophoresis (PAGE), transferred to
nitrocellulose membrane, and immunoblotted for ubiquitin.
Membranes were then stripped with Restore Western blot
stripping buffer (Pierce) and re-blotted for Htt. Membranes were
stripped a second time and immunoblotted for b-tubulin, used as a
loading control. The ratio of immunoprecipitated ubiquitin
(ubiquitinated Htt) to immunoprecipitated Htt (total Htt) was
assessed using chemiluminescence densitometry. Each band was
first normalized to the density of the b-tubulin band for that
sample. Immunoprecipitated Htt and ubiquitin levels were
compared by computing the ratio of the density of the band in
the presence of Happ1 to the density of the band in the presence of
VL12.3. The ratio of immunoprecipitated ubiquitin:Htt in the
presence of Happ1 vs. VL12.3 was then compared. The
experiment was repeated two additional times, giving an N of 3.
Htt levels
HEK 293 cells were transfected with mHDx-1-GFP plus iAb
(VL12.3, 1:1; Happ1, 2:1) or mHDx-1DPRR (lacking the proline-
rich region) plus iAb as a control for non-specific effects of Happ1.
Inhibitors of proteolytic processing were added to the culture
medium 24 hrs post-transfection in the following concentrations:
lactacystin (Sigma), 10 mM; epoxomicin (Sigma), 10 mM; 3-MA
(Sigma), 10 mM; bafilomycin A1 (Sigma), 100 nM; caspase
inhibitor I (NBD Biosciences), 50 mM; calpain inhibitor I (Sigma),
50 mM. Cell lysates were prepared for Western blotting 48 hrs
post-transfection as described above. Membranes were blotted for
Htt, and stripped and blotted for b-tubulin as a loading control.
Htt levels were compared by chemiluminescence densitometry.
The density of each band was normalized to the density of the b-
tubulin band for that sample. The ratio of Htt levels in the
presence of Happ1 to Htt levels in the presence of VL12.3 was
then compared. To reduce the likelihood that observed differences
in Htt level resulted from differences in transfection efficiency, the
experiment was repeated 3 times, giving an N of 4.
Htt turnover
Htt turnover was assayed using the SNAP-tag fusion system for in
vivo protein labeling (NEB) as previously described [14]. Briefly,
ST14A cells were grown on cover slips and transfected with mHDx-
1-SNAP alone or with iAb. To control for non-specific effects of
Happ1, mHDx-1DPRR–SNAP alone or with iAb was used. Green
fluorescent SNAP-substrate was added to cells 24 hrs post-
transfection to label all mHDx-1. Immediately after labeling, some
samples were fixed in 4% paraformaldehyde (PFA), stained for cell
nuclei (topro-3-iodide, Invitrogen) and mounted for confocal
microscopy. Inhibitors of proteolytic processing were then added
tothe mediumofthe remainingcultures.At48 hrspost-transfection,
these cells were fixed, stained and mounted as above. Mean intensity
of green fluorescence in cells in three microscope fields per well and
three wells for each condition was used to determine average Htt
levels.Theratioofmeancellintensityat24 hrstomeancellintensity
at 48 hrs was computed to determine rate of Htt turnover. The
experiment was repeated twice, giving an N of 3.
Calpain cleavage site prediction in HDx-1
Calpain 1 and calpain 2 cleavage sites in HDx-1 were predicted
using the SitePrediction tool with the pre-computed cleavage site
profiles ‘‘calpain-1_Homo_sapiens_4_2’’ and ‘‘calpain- 2_Homo_
sapiens_4_2’’ [16]. The HDx-1 sequence was obtained from the
February 2009 human reference sequence (GRCh37) through the
UCSCGenomeBrowser[17].PolyQtract lengthsof17and 42AAs
were used to determine if cleavage is modified by polyQ length.
In vitro calpain cleavage of HDx-1
HDx-1 Q46 fused to a thioredoxin tag (TRX) to promote
solubility (mHDx-1-TRX) was purified as reported previously [18]
and exchanged into diluent (20 mM Tris-HCl, pH 7.4 containing
150 mM NaCl and 2 mM Ca2
+) using a disposable PD10
desalting column (GE Healthcare). 20 mg purified mHDx-1-
TRX was incubated with 1 mg calpain 1 (Sigma) at 37uC for
1 hour. As a control for possible calpain cleavage in the TRX tag
or linker sequence, mHDx-1-TRX was cleaved with enterokina-
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entire TRX-linker sequence from mHDx-1-TRX according to the
manufacturer’s specifications. Cleavage reactions were separated
by PAGE and stained with coomassie to visualize protein bands.
Molecular weight of protein bands was determined by comparison
to precision plus dual protein molecular weight standard (Biorad)
using a FluorChem 8900 (Alpha Innotech) gel documentation
system and AlphaImager software. A reaction containing only
mHDx-1-TRX and diluent was used to assess uncleaved protein
and reactions containing either calpain 1 or EKMax and diluent in
the absence of mHDx-1-TRX were used to visualize bands
corresponding to these proteins. To identify cleavage fragments, a
reaction containing mHDx-1-TRX alone and one containing
mHDx-1-TRX and calpain were transferred to nitrocellulose
membrane after PAGE separation and blotted with an antibody
recognizing the N-terminus of Htt [19].
Peptide array mapping of the VL12.3 binding site
A 14-mer 7 peptide array covering Htt N1-32 in steps of three
AAs was purchased from Mimotopes. Peptides were dissolved in
80% DMSO/20% water to an average concentration of 5 mg/ml.
Peptides were further diluted 100-fold in water and 2 ml of each
peptide was blotted onto nitrocellulose and allowed to dry.
Nitrocellulose membranes were blocked with 1% milk in PBS for
one hour at room temperature. GST-VL12.3 generated as
previously described [14] was added as primary antibody and
incubated overnight at 4uC. After washing in PBS with 0.1%
Tween, anti-HA tag antibody 3F10 coupled to HRP (Roche) was
added for 1 hour at room temperature. Dot blots were developed
by exposure to X-ray film.
Organotypic brain slice cultures
Brain tissue was removed from euthanized postnatal day 10 (P10)
CD Sprague-Dawley rats (Charles River Laboratory, Raleigh, NC)
in accordance with Duke University Medical Center Institutional
Animal Care and Use Committee guidelines and approvals
(approval #A248-08-09), and as described previously [14,20].
250 mm thick coronal slices containing both striatum and cortex
were cut using Vibratomes (Vibratome, St. Louis, MO) in ice-cold
culture medium containing 15% heat-inactivated horse serum,
10 mM KCl, 10 mM HEPES, 100 U/ml penicillin/streptomycin,
1 mM MEM sodium pyruvate, and 1 mM L-glutamine in
Neurobasal A (Invitrogen). Corticostriatal brain slices were then
incubated at 37uC under 5% CO2 for 1 hr before biolistic
transfection with 1.6 mm gold particles coated with DNA constructs
expressing yellow fluorescent protein (YFP) as a vital marker,
mHDx-1 Q-73, and either VL12.3 or the CVL non-targeting
intrabody. For control transfections, gold particles were coated with
YFP alone plus vector backbone DNAs. For time resolved Fo ¨rster
resonance energy transfer (TR-FRET) analysis, brain slices were
triturated 10x through 26-gauge needles in ice-cold lysis buffer
(50 mM Tris-HCl, 150 nM NaCl, 2 mM EDTA, 1% NP-40, 0.1%
SDS + Roche protease inhibitor cocktail tablet) and centrifuged at
12,000 g for 10 min. at 4uC. The supernatants were collected and
stored at 280uC until TR-FRET analysis. Experimental conditions
were run in triplicate using a single brain slice per lysate.
Primary neuron co-culture
Cortico-striatal co-cultures were prepared as described in [21].
Briefly, cortices and striata from embryonic day 18 (E18) rat brains
were dissected then separately dissociated with papain/DNase
(Worthington biochemicals). Dissociated striatal and cortical
neurons were counted and 5610
6 cells each were separately co-
transfected by nucleofection (Amaxa, Lonza AG) with plasmids
encoding HDx-1 carrying 73 CAG repeats or empty vector and
either VL12.3 or the preimmune control CVL. After electropora-
tion, striatal and cortical cells were combined and 60,000 cells/
well were plated onto an established bed of astroglia in 96-well
plates. Astroglial feeder layers were generated by dissection of E18
cortices followed by three serial passages to establish an enriched
population of astroglia. Astroglia were plated into 96-well plates at
a density of 2000 cells/well three days before neuron plating.
Neurons were cultured in Neurobasal media (Invitrogen, Carls-
bad, CA) supplemented with 5% fetal calf serum (Sigma-Aldrich,
St. Louis, MO), 2 mM glutamine (Glutamax, Invitrogen), 10 mM
potassium chloride, and 5 mg/mL gentamicin at 37uC in 95% 02/
5%CO2 for 4–6 days before analysis.
For TR-FRET analysis, cells were harvested by scraping from
wells and triturating as described above for brain slice explants.
Soluble mHtt-TR-FRET assay
TR-FRET detection of soluble mHtt was previously described
[22]. In brief, samples were lysed in PBS, 0.4% TritonX100 and
Complete Protease Inhibitor (Roche). 5 ml sample plus 1 ml
antibody mix diluted in assay buffer (50 mM NaH2PO4, 400 mM
NaF, 0.1% BSA and 0.05% Tween) were pipetted per well of a low-
volume 384 microtiter plate (Sigma). Final antibody amount per
well was 1 ng 2B7-terbium cryptate-labeled antibody and 10 ng
MW1-D2-labeled antibody. Plates were incubated for 1 h at 4uC
and measured with a Xenon-lamp Envision Reader (PerkinElmer)
after excitation at 320 nm. Signal measured at 620 nm resulted
from the emission of the terbium cryptate-labeled antibody and was
used as a normalization signal for possible assay artifacts due to
scattering, quenching, absorption or sample turbidity. Mutant Htt
specific signal which resulted from thetime-delayed excitationofthe
D2-labeled MW1 antibody after excitation by the terbium cryptate
was detected at 665 nm. 665/620 nm signal ratio was calculated as
‘‘TR-FRET signal’’ specific for soluble mutant Htt.
Results
Happ1 does not increase mHDx-1 ubiquitination
To assess the effects of Happ1 on ubiquitination of mHDx-1,
HEK 293 cells were co-transfected with mHDx-1-GFP plus Happ1
or VL12.3. VL12.3 was used as a control for non-specific iAb effects
as wehavepreviously shown that thisiAbbinds mHDx-1buthas no
effect on its levels in this system [14]. Huntingtin was immunopre-
cipitated from transfected cell lysates and immunoblotted for both
Httand ubiquitin(Fig.1A). Densitometrywasused to determine the
ratio of ubiquitinated mHDx-1 to total mHDx-1 in the presence of
Happ1 versus VL12.3 (Fig. 1B). There is no differential effect of iAb
treatment on this ratio, indicating that Happ1 does not increase
mHDx-1 ubiquitination and therefore likely does not work through
a UPS-dependent mechanism.
Happ1-induced reduction of mHtt levels requires calpain
activity and maintenance of lysosomal pH
We previously showed that Happ1 stimulates mHDx-1 turnover
[14]. To determine which proteolytic pathway is involved, soluble
lysates of HEK 293 cells co-transfected with mHDx-1 plus iAb, or
mHDx-1DPRR plus iAb, and treated with various inhibitors of
proteolytic processing were immunoblotted for Htt (Fig. 2A). The
ratio of the Htt level in the presence of Happ1 to the Htt level in
the presence of VL12.3 was compared among the various
inhibitors. In unperturbed cells, or in the presence of DMSO
vehicle, the level of Htt in the presence of Happ1 is reduced
compared to the level of Htt in the presence of VL12.3. This ratio
is unchanged by the addition of various inhibitors: lactacystin, a
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epoxomicin, a proteasome inhibitor; 3-MA, an inhibitor of
autophagosome formation; or caspase inhibitor I, an irreversible
pan-caspase inhibitor. In contrast, the addition of bafilomycin A1,
an inhibitor of the vacuolar-type H(+)-ATPase that is known to
inhibit autophagosome/lysosome fusion as well as lysosomal pH;
or calpain inhibitor I, a pan-calpain inhibitor, significantly
increases the ratio of Htt in the presence of Happ1 to Htt in the
presence of VL12.3 (Fig. 2C). Thus, these latter two inhibitors
interfere with the mechanism by which Happ1 reduces the level of
mHtt. The levels of HDx-1 in the presence of calpain inhibitor I or
bafilomycin A1 are quantitatively very similar to those found using
the HDx-1 construct lacking the proline-rich region to which
Happ1 binds (Fig. 2B). Thus, it appears that these inhibitors
completely abolish the effect of Happ1 on mHDx-1 clearance.
The effect of bafilomycin A1 is likely due to disrupted lysosomal
pH rather than inhibition of autophagosome/lysosome fusion as
evidenced by the lack of effect by 3-MA, which should act
upstream of bafilomycin A1 in the macro-autophagy pathway.
Therefore, we infer that Happ1 reduces mHDx-1 level by a
calpain-CMA-dependent mechanism.
Happ1-induced stimulation of mHtt turnover requires
calpain activity and maintenance of lysosomal pH
In another approach to defining how Happ1 stimulates mHDx-
1 clearance, mHDx-1 was labeled with the SNAP reagent and the
loss of the label followed over time [23]. A traditional pulse chase
experiment was not used because mHDx-1 is known to affect
transcriptional regulation. This property of mHDx-1 could
conceivably be altered by iAb binding, leading to variable
transcription rates of HDx-1 in the presence of the various iAbs.
The SNAP-tag fusion system allows labeling of all preexisting
HDx-1. By measuring the amount of Htt at the time of labeling
and again at a later time point, we are able to measure a rate of
turnover independent of transcription or translation rate. This
system also offers greater specificity, because only the SNAP-tag
fusion protein is labeled as opposed to all cellular proteins
translated during the labeling period as with traditional pulse-
chase experiments. ST14A cells were transfected with mHDx-1-
SNAP alone or with iAb, as well as mHDx-1DPRR-SNAP alone
or with iAb. Green fluorescent SNAP substrate was used to label
mHDx-1 protein 24 hrs post-transfection (Fig. 3A). Cells were
allowed to incubate an additional 24 hrs in the presence of various
inhibitors of proteolytic processing or vehicle. The mean
fluorescence intensity of cells at 24 hrs and at 48 hrs was
compared to determine the amount of mHDx-1 labeled at
24 hrs that still remained at 48 hrs (Fig. 3B).
Compared to that in the presence of VL12.3, there is
significantly less mHDx-1 remaining at 48hrs in the presence of
Happ1. Addition of epoxomicin or 3-MA has no effect on the
turnover rate of mHDx-1 in the presence of Happ1, reinforcing
the conclusion that Happ1 does not increase mHDx-1 turnover by
enhancing proteasome or macroautophagy function. On the other
hand, addition of bafilomycin A1 or calpain inhibitor I completely
blocks the Happ1 stimulation of mHDx-1 turnover, leading to
turnover levels equivalent to those with mHDx-1 alone or in the
presence of VL12.3 (Fig. 3). These results support the finding with
Figure 1. Happ1 does not increase ubiquitination of mHDx-1. mHDx-1 was immunoprecipitated from the lysates of HEK 293 cells co-
transfected with mHDx-1 and iAb. (A) Lysates and IPs were Western blotted for Htt and ubiquitin. (B) The ratio of immunoprecipitated Htt (total
mHDx-1) to immunoprecipitated ubiquitin (ubiquitinated mHDx-1) was compared. There are no iAb specific effects on this ratio. N=3.
doi:10.1371/journal.pone.0016676.g001
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by enhancing calpain cleavage and CMA.
A turnover rate could not be assessed for mHDx-1DPRR due to
the increased toxicity and aggregation of this construct, leading to
a paucity of morphologically normal cells or soluble HDx-1 at 48
hrs (Fig. 4). There is still significant soluble HDx-1 in the presence
of VL12.3 at this time point, indicating that, as expected from our
previous work, this iAb inhibits aggregation of this modified HDx-
1, while Happ1 does not.
There are putative calpain cleavage sites at AA 15 and AA
8 of HDx-1
To identify the site of calpain action, human HDx-1 amino acid
sequence was analyzed for potential calpain 1 and 2 cleavage sites
using the web application SitePrediction [16]. Using this program,
AAs 12–17 with cleavage between 15 and 16, (ESLK.SF), is
predicted to be the most likely site for both proteases, with greater
than 99.9% specificity for calpain 1 and greater than 99%
specificity for calpain 2. A secondary site at AAs 5–10, with
cleavage between 8 and 9, (EKLM.KA), is predicted to have
greater than 99% specificity for calpain 1 and greater than 95%
specificity for calpain 2 (Fig. S1).
Calpain 1 cleaves mHDx-1 in vitro
To determine if calpain directly or indirectly promotes clearance
of mHDx-1 we incubated purified, recombinant calpain 1 and
mHDx-1 protein in vitro. A thioredoxin tag (TRX) was fused to
mHDx-1 to promote solubility. Cleavage at the predicted calpain
recognition sites would result in N-terminal fragments consisting of
the TRX tag and linkerand N1-8 or N1-15 (Fig. 5a) As a controlfor
cleavage within the TRX tag, mHDx-1-TRX was also incubated
with EKMax, which removes the entire tag and linker sequence.
Reactions containing either no protease or no HDx-1-TRX were
used as controls. Reactions were separated by PAGE and visualized
Figure 2. Happ1-mediated reduction of mHDx-1 protein levels is calpain-dependent. HEK 293 cells were co-transfected with mHDx-1 and
iAb in the presence of inhibitors of proteolysis or DMSO vehicle. mHDx-1 protein levels in transfected cell lysates was compared by (A, B) Western
blotting and (C) densitometry. There is less mHDx-1 protein in the Happ1 transfected cells as compared to the VL12.3 transfected cells in the presence
of vehicle, Lactacystin, epoxomicin, 3-MA or caspase inhibitor 1. Happ1-mediated reduction of mHDx-1 levels is blocked by bafilomycin A1 or calpain
inhibitor 1 to the same level as mHDx-1 lacking the Happ1 binding site. *=p,.05, N=4.
doi:10.1371/journal.pone.0016676.g002
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mHDx-1-TRX protein appears as a single band of approximately
46 kDa. In the presence of calpain 1, mHDx-1-TRX is cleaved
resulting in three smaller products (Fig. 5b). The smallest of these
are 15.2 and 16.0 kDawhich arevery close to the predicted sizes for
N1-8-TRX and N1-15-TRX of 15.1 and 15.9 kDa supporting
cleavage at the predicted sites. These products are larger than those
generated by EKMax cleavage indicating that calpain cleavage is
occurring within mHDx-1. Immunoblotting with an antibody
recognizing the N-terminus of Htt confirms that the 16.0 kDa
cleavage fragment contains this domain supporting the predicted
cleavage site (Fig. S2).
VL12.3 binds to the putative calpain cleavage site at AA
15
The iAb VL12.3 was selected for binding to an N1-20 AA
fragment of HDx-1 [24], a domain that encompasses but is not
limited to the predicted calpain cleavage sites. To determine the
Figure 3. Happ1-enhanced mHDx-1 turnover is calpain-dependent. ST14A cells were co-transfected with mHDx-1-SNAP alone or with iAb in
the presence of inhibitors of proteolytic processing or DMSO vehicle. To measure Htt turnover, mHDx-1 protein was labeled 24 Hrs post transfection
and cultures were incubated for an additional 24 Hrs. (A) Immunofluorescent images showing labeled mHDx-1 (B) The mean cell intensity of label at
24 Hrs vs. 48 Hrs was used to determine the percentage of mHDx-1 labeled at 24 Hrs that still remained at 48 Hrs. In the presence of epoxomicin or
3M-A there is no change in Happ1-enhanced mHDx-1 turnover as compared to in the presence of DMSO. In the presence of bafilomycin A1 or calpain
inhibitor 1, mHDx-1 turnover is not increased by Happ1. *=p,.05, **=p,.01, N=3.
doi:10.1371/journal.pone.0016676.g003
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array binding assay (Fig. 6A). The results show that VL12.3 binds
to peptides 3, 4 and 5 which are N7-20, N10-23 and N13-26,
respectively (Fig. 6B). This demonstrates that VL12.3 requires AAs
15-18 at the minimum and 13–20 at the maximum for binding.
Thus, VL12.3 binding would be expected to interfere with
cleavage at AA 15 and possibly sterically hinder cleavage at AA 8.
Blocking cleavage at AA 15 by VL12.3 binding prevents
clearance of soluble mHDx-1
To determine the effect of compromising cleavage at AA 15 on
mHDx-1 clearance, we performed a TR-FRET assay to measure
soluble mHDx-1 levels in lysates of organotypic brain slice cultures
biolistically transfected with mHDx-1 alone or with either VL12.3
or CVL, a control iAb. Soluble mHtt levels were compared 1, 2
and 3 days post-transfection by measuring the TR-FRET signal
between a donor fluorophore-labeled antibody, 2B7, recognizing
N1-17 of HDx-1, and an acceptor fluorophore-labeled antibody,
MW1, recognizing polyQ [22]. This system is more suited to the
measurement of reduced mHDx-1 turnover than the SNAP-tag
fusion system described above, in which we observed no effect of
VL12.3 on turnover rate. The brain slice culture system allows for
longer experimental time frames during which, unlike the SNAP-
tag system, significant normal mHDx-1 clearance is observed. This
system also utilizes non-tagged mHDx-1 decreasing the likelihood
that observed changes in mHDx-1 level are due to conformation
or stability perturbations resulting from tag fusion. As expected,
the level of soluble mHDx-1 in the presence of CVL declines over
time, reflecting normal clearance. In the presence of VL12.3, there
is no change in mHDx-1 levels over time indicating a complete
block of clearance (Fig. 7a). To extend our observation period even
further, we have utilized a primary neuronal co-culture system
consisting of striatal and cortical neurons as well as glia [21].
Primary neurons were transfected with iAb or mHDx-1 plus iAb
and plated on a previously generated glial bed. Lysates were
collected 4, 5 or 6 days later, and mHDx-1 protein level was
assessed by TR-FRET. At these later time points, there is
dramatically more mHDx-1 protein in the presence of VL12.3
than in the presence of CVL (Fig. 7b). This suggests that clearance
of mHDx-1 requires calpain cleavage at AA15, and that this
cleavage event likely occurs upstream of CMA degradation.
Discussion
Huntington’s disease is a devastating neurodegenerative disease
for which there is currently no disease modifying therapy. One of
the difficulties with HD therapy development is the complex web
of dysfunction resulting from the great many processes and
pathways affected by mHtt protein in susceptible neurons. As a
result, lowering the level of mHtt protein either by silencing
expression or increased clearance remains a prime therapeutic
approach for HD. For this reason, understanding the mechanism
of mHtt degradation is important.
Huntingtin degradation involves numerous pathways, with
differential toxicity regulated by post-translational modifications.
Transgenic mice expressing mHtt that is resistant to caspase-6
cleavage at AA 586 do not develop the HD-like symptoms seen in
their caspase-6-sensitive counterparts, despite the presence of
other caspase cleavage products in the brain [9]. Phosphorylation
of serine 421 shifts processing toward these less toxic products by
inhibiting cleavage at AA 586 [11]. Moreover, calpain-resistant
mHtt lacking the AA 469 and AA 536 cleavage sites is less toxic
and aggregation-prone than calpain cleavage-sensitive mHtt [10].
Phosphorylation of serine 536 inhibits cleavage at AA 536, which
also results in reduced toxicity [25]. Modifications of mHtt can
also regulate non-protease degradation events. Phosphorylation of
serines 13 and 16 increases proteasomal and lysosomal degrada-
tion of Htt in turn reducing toxicity. In Drosophila, presumably due
to the absence of mammalian degradative machinery and
mechanisms, this modification leads to increased toxicity due to
accumulation of the more toxic phosphorylated form of mHtt
[12]. A better understanding of the complex process of mHtt
proteolysis could eventually lead to the development of therapeu-
tics that shift processing toward less toxic pathways and/or
enhance removal. Although the generation of N-terminal mHtt
fragments by caspase and calpain cleavage has been previously
characterized, the subsequent degradation of the highly toxic
HDx-1 fragment has remained unclear.
With their high target specificity, iAbs are an ideal molecular
tool for elucidating protein interactions and functions. For
example, the 17 N-terminal AAs of HDx-1 are required for
aggregate seeding and cytoplasmic retention [26,27]. Blockade of
this region by the binding of the iAb VL12.3 results in nuclear
translocation and a potent inhibition of aggregation of HDx-1,
illustrating the informative relationship between iAb effects and
epitope function [14,24]. Happ1 recognizes the proline rich region
of HDx-1 and increases clearance of mutant but not wild type
HDx-1 [14]. We have exploited this effect of Happ1 binding to
gain insight into the mechanism of HDx-1 proteolysis.
Htt undergoes a variety of proteolytic processing steps
including protease cleavage, proteasomal degradation, and
lysosomal/autophagic degradation. In order to determine the
initiating or rate-limiting step in mHDx-1 degradation, we tested
inhibitors of each of these pathways in the presence and absence
of Happ1 and evaluated mHDx-1 levels and turnover using the
SNAP-tag method. One caveat of this method is that it requires
the use of tagged HDx-1, which could alter HDx-1 conformation
or stability. However, we obtained supportive evidence for the
effect of VL12.3 on unlabeled HDx-1 using the entirely
independent TR-FRET technique. Moreover, the stimulatory
effect of Happ1 on mHDx-1 turnover labeled with the SNAP-tag
is quite consistent with the significant lowering of mHDx-1-GFP
levels by Happ1. An important control in our experiments is the
use of mHDx-1DPRR, which lacks the Happ1 binding site.
Levels of this protein are not affected by Happ1, indicating that
the reduced mHDx-1 levels in the presence of Happ1 do not
Figure 4. Happ1 does not inhibit aggregation of mHDx-1DPRR.
ST14A cells were co-transfected with mHDx-1DPRR-SNAP alone or with
iAb. HDx-1-SNAP fusion protein was labeled 24 Hrs post transfection,
and labeled protein was observed 24 Hrs later. As expected, Happ1 has
no effect on aggregation of mHDx-1 lacking the Happ1 binding site.
Conversely, VL12.3 is still efficient at preventing aggregation of this
modified mHDx-1.
doi:10.1371/journal.pone.0016676.g004
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folded protein response [28].
The proteasome inhibitors epoxomicin and lactacystin do not
disrupt Happ1 stimulation of HDx-1 turnover, and Happ1 does not
increaseubiquitinationofHDx-1.These resultsindicatethatHapp1
does not accelerate proteasomal degradation of Htt. We also find
that 3-MA, an inhibitor of autophagosome formation and the
macroautophagy pathway, does not interfere with Happ1-acceler-
ated mHDx-1 degradation. In contrast, bafilomycin A1, a vacuolar-
type H(+)-ATPase inhibitor that hinders lysosome-autophagosome
fusion as well as disrupting lysosomal pH, prevents Happ1-induced
changes in mHDx-1 clearance rate. Due to the lack of effect of 3-
MA, it is unlikely that the action of bafilomycin A1 on
autophagosome/lysosome fusion is responsible for disrupting
Happ1 function. It is more likely that bafilomycin A1 disrupts
Happ1 function by disrupting lysosomal pH. This indicates a role
for CMA, which is an autophagosome-independent lysosomal
degradation process, in Happ1-enhanced mHDx-1 clearance.
We next evaluated the sensitivity of the Happ1 effects to the
caspase and calpain proteases. While caspase inhibition has no
effect on Happ1 function, calpain inhibition is effective in blocking
the ability of Happ1 to both decrease the level of soluble mHDx-1
and increase its turnover. These results indicate that Happ1 likely
increases mHDx-1 clearance through enhanced calpain cleavage,
which is particularly interesting because of the lack of a known
calpain cleavage site in HDx-1. Calpain inhibitor I has, however,
been reported to cause accumulation and increased aggregation of
N-terminal Htt fragments including HDx-1, and calpain 1 is
known to increase degradation of these fragments in the lysates of
transfected PC12 cells [29]. Taken together, these results indicate
that calpains participate either directly or indirectly in the
degradation of mHDx-1.
Analysis of the AA sequence of human HDx-1 using the web
application SitePrediction identifies AAs 12-17 as having the
highest degree of specificity for both calpain 1 and calpain 2, with
a secondary recognition site at AA 5-10. Cleavage at these sites,
which is not predicted to be modulated by increasing polyQ
length, would result in the removal of 15 of the 17 N-terminal AAs
of Htt, effectively removing the N-terminus. The N-terminus of
Htt is the site of many post-translational modifications including
phosphorylation, acetylation and sumoylation [30,31]. In the wt
protein, this domain adopts an amphipathic alpha-helical
Figure 5. Purified calpain 1 cleaves HDx-1 in vitro generating cleavage fragments consistent with the predicted sites at AA8 and
AA15. HDx-1 Q46 fused to thioredoxin (mHDx-1-TRX) was incubated with purified calpain 1 in vitro, separated by PAGE and stained with coomassie
to assess cleavage. (A) mHDx-1-TRX construct showing known EKMax cleavage sites and predicted calpain 1 cleavage sites. (B) Coomassie stained
PAGE gel showing mHDx-1-TRX in lane 1, which appears as a single band. Cleavage by calpain 1 in lane 2 yields 3 smaller bands which correspond to
the predicted products after cleavage at AA 8 and AA 15. Cleavage by EKMax in lane 3 yields 3 bands which correspond to the known cleavage sites.
The N-terminal fragments generated by EKMax cleavage, which include the entire TRX tag and linker, are smaller than those generated by calpain
cleavage indicating that calpain cleavage must occur within HDx-1. Lanes 4 and 5 are calpain 1 alone and EKMax alone respectively.
doi:10.1371/journal.pone.0016676.g005
Calpain Cleaves Huntingtin Exon 1
PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16676structure, which associates with cellular membranes [26,32]. The
predicted cleavage site, AA15, is part of the charged face of this
helix and would therefore be exposed, but the tightly packed
nature of this secondary structure could inhibit cleavage. In the
context of expanded polyQ, the secondary structure of the N-
terminus is significantly disrupted [33] leading to an un-coiling,
which could increase exposure of the predicted cleavage site. This
could explain the differential action of Happ1 on mutant and
wtHtt. It is interesting to note that phosphorylation of this putative
calpain cleavage site is known to increase mHDx-1 nuclear
localization followed by degradation [12] and that removal of the
N-terminus is known to increase nuclear localization [26,27].
Calpain I cleaves purified mHDx-1 in vitro, generating cleavage
products of the expected sizes, showing that this protease can act
directly on HDx-1 and supporting the site prediction. We
employed iAb blockade of the N-terminal 12-17 AA site to
determine the importance of cleavage here in the degradative
process. VL12.3 was raised against a peptide of AAs 1–20 of Htt
and therefore binds somewhere in this region [24], which includes
but is not limited to the putative calpain cleavage sites identified
here. Peptide array epitope mapping shows that VL12.3 binding
requires at a minimum, AAs 15–18 of HDx-1 for binding, a region
that includes the putative calpain cleavage site at AA 15. As
VL12.3 binding is known to prevent interactions of HDx-1 that
require this domain, such as aggregate seeding and cytoplasmic
retention [14], it is reasonable to postulate that VL12.3 would also
compromise cleavage here. If calpain cleavage at this site is
involved in the degradation of mHDx-1, VL12.3 binding would be
expected to reduce turnover. We have previously shown that
VL12.3 binding has no effect on mHDx-1 protein level or turnover
rate in cultured 293 and ST14A cells, respectively [14]. These
systems are, however, temporally constrained by the toxicity of
transfection reagents and mHDx-1 as well as cell proliferation.
These factors limit our experimental time frame to 24 Hrs, an
interval in which we observe very little normal mHDx-1 clearance,
and any decreases in clearance may be below the sensitivity
threshold of the assays. As a result, these systems, although
sufficient for evaluating increased turnover, are inadequate for
evaluating decreased turnover. Moreover, these systems lack
differentiated neurons and connectivity, which are integral to
HD pathology and require the use of GFP or SNAP-tag fusions,
which could alter mHDx-1 stability. In an effort to overcome these
caveats, we used a TR-FRET assay to evaluate the effect of
VL12.3 on non-tagged mHDx-1 clearance in biolistically co-
transfected brain slice explants and in primary corticostriatal
neuronal co-cultures, which allow longer experimental time frames
of up to 3 and 6 days, respectively, in more relevant, partially
intact neuronal systems. In these systems in the presence of CVL,
an iAb that does not bind HDx-1, the level of mHDx-1 protein
appears to decline over the first three days, reaching a plateau that
is maintained for the subsequent 3 days, reflecting normal
turnover. Conversely, during the observed time period there is
Figure 6. VL12.3 recognizes AAs 13-20 of HDx-1. Three AA
stepped 14-mer peptides were spotted onto nitrocellulose and binding
of VL12.3 was assessed. (A) Peptide table. (B) Dot blot showing binding
of peptides 3, 4 and 5 illustrating that VL12.3 requires AAs 15-18 at the
minimum and 13-20 at the maximum for recognition of Htt.
doi:10.1371/journal.pone.0016676.g006
Figure 7. VL12.3 binding prevents turnover of HDx-1. (A) Organotypic brain slice cultures were co-transfected with mHDx-1 and VL12.3 or CVL,
a control iAb. Soluble mHDx-1 protein level was assessed in lysates collected 1, 2 or 3 days post-transfection by TR-FRET. The level of mHDx-1 protein
declines over time in the presence of CVL, but not in the presence of VL12.3 indicating impaired clearance. (B) Primary striatal and cortical neurons co-
cultured with astroglia were transfected with iAb or mHDx-1 plus iAb. Soluble mHDx-1 protein level was assessed in lysates collected 4, 5 or 6 days
post-transfection by TR-FRET. At these later time points, there is dramatically more mHDx-1 protein in the presence of VL12.3 as compared to CVL.
doi:10.1371/journal.pone.0016676.g007
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demonstrating a lack of normal turnover when the putative
calpain cleavage site is bound by the iAb. These results suggest
that calpain-mediated removal of the N-terminus of mHDx-1,
which is likely followed by CMA degradation, is required for
clearance of this toxic protein and that selective regulation of this
cleavage event could prove beneficial in the treatment or
prevention of HD.
Supporting Information
Figure S1 There are predicted calpain cleavage sites at
AAs 12-17 and 5-10 of HDx-1 with high specificity for
calpains 1 and 2. Human HDx-1 sequence was analyzed using
the web tool SitePrediction for predicted calpain 1 and 2 cleavage
sites. This analysis determined that AAs 12-17 is predicted to have
the greatest specificity for both proteases. There is a secondary
predicted cleavage site at AA 5-10 that is also predicted to be
highly specific for both calpain 1 and 2.
(TIF)
Figure S2 The 16.0 kDa calpain cleavage fragment
contains the Htt N-terminus. HDx-1 Q46 fused to thior-
edoxin (mHDx-1-TRX) was incubated alone or with purified
calpain 1 in vitro, separated by PAGE and transferred to
nitrocellulose membrane. Immunoblotting with an antibody
recognizing the N-terminus of Htt reveals that the 16.0 kDa
cleavage product contains this domain.
(TIF)
Acknowledgments
We thank David Colby and K. Dane Wittrup for VL12.3, Elena Cattaneo
for ST14A cells, Pamela Bjorkman for mHDx-1-TRX, Vivian Hook for
anti-Htt N1-17 antibody, Christian Essrich for the design and piloting of
the brain slice experiments, and Ali Khoshnan and Rona Graham for
discussion and support.
Author Contributions
Conceived and designed the experiments: ALS CWB PP DCL PHP.
Performed the experiments: ALS CWB LSK DD SB AW. Analyzed the
data: ALS CWB SB AW. Wrote the paper: ALS DCL PHP.
References
1. The Huntington’s Disease Collaborative Research Group (1993) A novel gene
containing a trinucleotide repeat that is expanded and unstable on Huntington’s
disease chromosomes. Cell 72: 971–983.
2. Imarisio S, Carmichael J, Korolchuk V, Chen C-W, Saiki S, et al. (2008)
Huntington’s disease: from pathology and genetics to potential therapies.
Biochem J 412: 191–209.
3. Gil JM, Rego AC (2008) Mechanisms of neurodegeneration in Huntington’s
disease. Eur J Neurosci 27: 2803–2820.
4. Qin Z-H, Gu Z-L (2004) Huntingtin processing in pathogenesis of Huntington
disease. Acta Pharmacol Sin 25: 1243–1249.
5. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, et al. (2010)
Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That
Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington
Disease. J Biol Chem 285: 8808–8823.
6. Ratovitski T, Gucek M, Jiang H, Chighladze E, Waldron E, et al. (2009) Mutant
Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and
Toxicity in Neuronal Cells. J Biol Chem 284: 10855–10867.
7. Majumder P, Raychaudhuri S, Chattopadhyay B, Bhattacharyya NP (2007)
Increased caspase-2, calpain activations and decreased mitochondrial complex II
activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat
in the pathogenic range. Cell Mol Neurobiol 27: 1127–1145.
8. Todde V, Veenhuis M, van der Klei IJ (2009) Autophagy: Principles and
significance in health and disease. BBA - Mol Basis Dis 1792: 3–13.
9. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, et al. (2006) Cleavage at the
caspase-6 site Is required for neuronal dysfunction and degeneration due to
mutant huntingtin. Cell 125: 1179–1191.
10. Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, et al. (2004)
Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of
calpain/caspase fragments in the nucleus. J Biol Chem 279: 20211–20220.
11. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, et al. (2009)
Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments.
Mol Cell Neurosci 40: 121–127.
12. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, et al. (2009)
IKK phosphorylates huntingtin and targets it for degradation by the proteasome
and lysosome. J Cell Biol 187: 1083–1099.
13. Southwell AL, Patterson PH (2010) Antibody therapy in Neurodegenerative
disease. Rev neurosci In press.
14. Southwell AL, Khoshnan A, Dunn DE, Bugg CW, Lo DC, et al. (2008)
Intrabodies binding the proline-rich domains of mutant huntingtin increase its
turnover and reduce neurotoxicity. J Neurosci 28: 9013–9020.
15. Southwell AL, Ko J, Patterson PH (2009) Intrabody Gene Therapy Ameliorates
Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models
of Huntington’s Disease. J Neurosci 29: 13589–13602.
16. Verspurten J, Gevaert K, Declercq W, Vandenabeele P (2009) SitePredicting the
cleavage of proteinase substrates. Trends Biochem Sci 34: 319–323.
17. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The
human genome browser at UCSC. Genome Res 12: 996–1006.
18. Bennett MJ, Huey-Tubman KE, Herr AB, West AP, Ross SA, et al. (2002) A
linear lattice model for polyglutamine in CAG-expansion diseases. PNAS 99:
11634–11639.
19. Mende-Mueller LM, Toneff T, Hwang S-R, Chesselet M-F, Hook VYH (2001)
Tissue-Specific Proteolysis of Huntingtin (htt) in Human Brain: Evidence of
Enhanced Levels of N- and C-Terminal htt Fragments in Huntington’s Disease
Striatum. J Neurosci 21: 1830–1837.
20. Lo DC, McAllister AK, Katz LC (1994) Neuronal transfection in brain slices
using particle-mediated gene transfer. Neuron 13: 1263–1268.
21. Kaltenbach LS, Bolton MM, Shah B, Kanju PM, Lewis GM, et al. (2010)
Composite primary neuronal high-content screening assay for Huntington’s
disease incorporating non-cell-autonomous interactions. J Biomol Screen 15:
806–819.
22. Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, et al. (2009) Single-step
detection of mutant huntingtin in animal and human tissues: A bioassay for
Huntington’s disease. Anal Biochem 395: 8–15.
23. Jansen LET, Black BE, Foltz DR, Cleveland DW (2007) Propagation of
centromeric chromatin requires exit from mitosis. J Cell Biol 176: 795–805.
24. Colby DW, Garg P, Holden T, Chao G, Webster JM, et al. (2004) Development
of a human light chain variable domain (VL) intracellular antibody specific for
the amino terminus of huntingtin via yeast surface display. J Mol Biol 342:
901–912.
25. Schilling B, Gafni J, Torcassi C, Cong X, Row RH, et al. (2006) Huntingtin
phosphorylation sites mapped by mass spectrometry: modulation of cleavage
and toxicity. J Biol Chem 281: 23686–23697.
26. Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, et al. (2007) Huntingtin has a
membrane association signal that can modulate huntingtin aggregation, nuclear
entry and toxicity. Hum Mol Genet 16: 2600–2615.
27. Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, et al. (2007)
The first 17 amino acids of Huntingtin modulate its sub-cellular localization,
aggregation and effects on calcium homeostasis. Hum Mol Genet 16: 61–77.
28. Schroder M, Kaufman RJ (2005) The mammalian unfolded protein response.
Ann Rev Biochem 74: 739–789.
29. Ratovitski T, Nakamura M, D’Ambola J, Chighladze E, Liang Y, et al. (2007) N-
terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell
model of Huntington’s disease. Cell Cycle 6: 2970–2981.
30. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, et al. (2004)
SUMO modification of duntingtin and Huntington’s disease pathology. Science
304: 100–104.
31. Aiken CT, Steffan JS, Guerrero CM, Khashwji H, Lukacsovich T, et al. (2009)
Phosphorylation of Threonine 3: Implications for huntingtin aggregation and
neurotoxicity. J Biol Chem 284: 29427–29436.
32. Kim MW, Chelliah Y, Kim SW, Otwinowski Z, Bezprozvanny I (2009)
Secondary Structure of Huntingtin Amino-Terminal Region. Structure 17:
1205–1212.
33. Thakur AK, Jayaraman M, Mishra R, Thakur M, Chellgren VM, et al. (2009)
Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex
aggregation mechanism. Nat Struct Mol Biol advanced online publication.
Calpain Cleaves Huntingtin Exon 1
PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e16676